Latest news with #Timashev
Business Insider
20-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pyxis Oncology (PYXS – Research Report), Globus Medical (GMED – Research Report) and Ramsay Health Care (RMSYF – Research Report). Confident Investing Starts Here: Pyxis Oncology (PYXS) In a report issued on May 15, Leonid Timashev from RBC Capital maintained a Buy rating on Pyxis Oncology, with a price target of $8.00. The company's shares closed last Monday at $1.23, close to its 52-week low of $0.99. According to Timashev is a 1-star analyst with an average return of -0.5% and a 32.8% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Edgewise Therapeutics, and Design Therapeutics. Currently, the analyst consensus on Pyxis Oncology is a Strong Buy with an average price target of $6.83, representing a 483.8% upside. In a report issued on May 16, Leerink Partners also maintained a Buy rating on the stock with a $7.00 price target. Globus Medical (GMED) RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical on May 15 and set a price target of $95.00. The company's shares closed last Monday at $61.05. According to Chadha is a 2-star analyst with an average return of 0.5% and a 48.6% success rate. Chadha covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Tandem Diabetes Care. Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $87.38, implying a 44.6% upside from current levels. In a report issued on May 8, Morgan Stanley also maintained a Buy rating on the stock with a $100.00 price target. Ramsay Health Care (RMSYF) RBC Capital analyst Craig Wong-Pan maintained a Hold rating on Ramsay Health Care on May 15 and set a price target of A$41.00. The company's shares closed last Thursday at $22.00. According to Wong-Pan is ranked #7861 out of 9558 analysts. Ramsay Health Care has an analyst consensus of Hold, with a price target consensus of $25.32, implying an 11.2% upside from current levels. In a report issued on May 5, Morgan Stanley also maintained a Hold rating on the stock with a A$37.20 price target.
Business Insider
13-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and GH Research (GHRS)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS – Research Report) and GH Research (GHRS – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. COMPASS Pathways (CMPS) In a report issued on May 8, Leonid Timashev from RBC Capital maintained a Buy rating on COMPASS Pathways, with a price target of $15.00. The company's shares closed last Monday at $3.91, close to its 52-week low of $2.88. According to Timashev is a 2-star analyst with an average return of -0.5% and a 31.6% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Edgewise Therapeutics, and Axsome Therapeutics. COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $18.75, representing a 368.8% upside. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $23.00 price target. GH Research (GHRS) RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research on May 8 and set a price target of $32.00. The company's shares closed last Monday at $10.16. According to Abrahams ' ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.0% and a 40.0% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., MoonLake Immunotherapeutics, and Neumora Therapeutics, Inc. Currently, the analyst consensus on GH Research is a Strong Buy with an average price target of $31.43, representing a 199.9% upside. In a report issued on May 9, Guggenheim also maintained a Buy rating on the stock with a $29.00 price target.
